ArticleJournal of general internal medicine2023
Model-Projected Cost-Effectiveness of Adult Hearing Screening in the USA.
Article in Journal of general internal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- The impact of hearing loss on annual incident age-associated dementia cases and quality of life in the United States.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Targeted adult hearing loss screening in the UK: policy options for equitable implementation through health-service pathways.Frontiers in public health · 2026Article
- Can hearing screening criteria at general health checkups be an indirect indicator of frailty and cognitive deficit in the older population? - with prevalence estimates based on updated World Health Organization hearing loss classification.Geriatrics & gerontology international · 2025Article
- The influence of targeted therapies in the inner ear.Frontiers in pharmacology · 2025Review
- An electrophysiological early marker of age-related hearing loss in the Wistar rat model.Heliyon · 2024Article
- Towards universal access: A review of global efforts in ear and hearing care.Hearing research · 2024Review
- Potential Clinical and Economic Outcomes of Over-the-Counter Hearing Aids in the US.JAMA otolaryngology-- head & neck surgery · 2023Article
- Estimated Monetary Value of Future Research Clarifying Uncertainties Around the Optimal Adult Hearing Screening Schedule.JAMA health forum · 2022Article
- Public Awareness of Hearing Aids and Cochlear Implants: A Google Trends Analysis of Media Campaigns.OTO openArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundWhile 60% of older adults have hearing loss (HL), the majority have never had their hearing tested.
objectiveWe sought to estimate long-term clinical and economic effects of alternative adult hearing screening schedules in the USA.
designModel-based cost-effectiveness analysis simulating Current Detection (CD) and linkage of persons with HL to hearing healthcare, compared to alternative screening schedules varying by age at first screen (45 to 75 years) and screening frequency (every 1 or 5 years). Simulated persons experience yearly age- and sex-specific probabilities of acquiring HL, and subsequent hearing aid uptake (0.5-8%/year) and discontinuation (13-4%). Quality-adjusted life-years (QALYs) were estimated according to hearing level and treatment status. Costs from a health system perspective include screening ($30-120; 2020 USD), HL diagnosis ($300), and hearing aid devices ($3690 year 1, $910/subsequent year). Data sources were published estimates from NHANES and clinical trials of adult hearing screening.
participantsForty-year-old persons in US primary care across their lifetime.
interventionAlternative screening schedules that increase baseline probabilities of hearing aid uptake (base-case 1.62-fold; range 1.05-2.25-fold). MAIN MEASURES: Lifetime undiscounted and discounted (3%/year) costs and QALYs and incremental cost-effectiveness ratios (ICERs). KEY
resultsCD resulted in 1.20 average person-years of hearing aid use compared to 1.27-1.68 with the screening schedules. Lifetime total per-person undiscounted costs were $3300 for CD and ranged from $3630 for 5-yearly screening beginning at age 75 to $6490 for yearly screening beginning at age 45. In cost-effectiveness analysis, yearly screening beginning at ages 75, 65, and 55 years had ICERs of $39,100/QALY, $48,900/QALY, and $96,900/QALY, respectively. Results were most sensitive to variations in hearing aid utility benefit and screening effectiveness. LIMITATION: Input uncertainty around screening effectiveness.
conclusionsWe project that yearly hearing screening beginning at age 55+ is cost-effective by US standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.